GLULP4: A Potential Drug Target and Biomarker (G392305)

Target Name: GLULP4

NCBI ID: G392305

GLULP4

Other Name(s): GLULP | Glutamate-ammonia ligase (glutamine synthetase) pseudogene 4 | glutamate-ammonia ligase pseudogene 4

GLULP4: A Potential Drug Target and Biomarker

GLULP4 (G-CSF-1-like protein 4) is a protein that is expressed in various tissues, including the brain, heart, and kidneys, and has been shown to play a role in various physiological processes. GLULP4 has also been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

GLULP4 is a member of the G-CSF family, which includes several other proteins that play a role in the production and regulation of granulocyte-colony stimulating factor (GCGF), a protein that is involved in the development and function of granulocytes, a type of white blood cell that plays a critical role in immune responses and inflammation. The G-CSF family of proteins is also known as the GLULP family, as the name is derived from the last two letters of the protein name.

GLULP4 is a 21-kDa protein that is expressed in various tissues, including the brain, heart, and kidneys. It is highly expressed in the brain and has been shown to play a role in the development and function of neural cells, including neurons and glial cells. GLULP4 has also been shown to be involved in the regulation of various cellular processes, including cell adhesion, migration, and survival.

GLULP4 has also been identified as a potential drug target for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, GLULP4 has been shown to be involved in the development and progression of various types of cancer, including neurobladder cancer and breast cancer. Additionally, GLULP4 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

GLULP4 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, GLULP4 has been shown to be involved in the diagnosis and prognosis of various types of cancer, including breast and ovarian cancer. Additionally, GLULP4 has been shown to be involved in the diagnosis and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In conclusion, GLULP4 is a protein that has been shown to play a critical role in various physiological processes and has been identified as a potential drug target and biomarker for several diseases. Further research is needed to fully understand the role of GLULP4 in these processes and to develop effective treatments for GLULP4-related diseases.

Protein Name: Glutamate-ammonia Ligase Pseudogene 4

The "GLULP4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GLULP4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets